Synergy Pharmaceuticals (SGYP) : Zacks Investment Research ranks Synergy Pharmaceuticals (SGYP) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 2 research analysts is 1, which indicates as a Strong Buy.
Synergy Pharmaceuticals (SGYP) : 2 Wall Street analysts covering Synergy Pharmaceuticals (SGYP) believe that the average level the stock could reach for the short term is $10.75. The maximum price target given is $15 and the minimum target for short term is around $7, hence the standard deviation is calculated at $6.01.
For the current week, the company shares have a recommendation consensus of Buy. Synergy Pharmaceuticals (NASDAQ:SGYP): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.70 and $4.66 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.88. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.78, notching a gain of 3.24% for the day. The total traded volume was 2,410,399 . The stock had closed at $4.63 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Denoyer Bernard, officer (Senior Vice President, Finance) of Synergy Pharmaceuticals, Inc., had unloaded 10,000 shares at an average price of $7.5 in a transaction dated on September 14, 2015. The total value of the transaction was worth $75,000.
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.